Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PROKR2 | Q8NFJ6 | 5/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.30 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436784 | 1.00 | PROKR2 (1.00) | PROKR2PKMHTR2AHTR2CMAPK8 | |
| SCHEMBL19451845 | 0.89 | PROKR2 (0.80) | PROKR2MAPK8MAP3K7TAB1 | |
| SCHEMBL19451847 | 0.89 | PROKR2 (0.80) | PROKR2MAPK8MAP3K7TAB1 | |
| SCHEMBL564196 | 0.87 | PROKR2 (0.77) | PROKR2PKMMAPK8MAP3K7TAB1 | |
| SCHEMBL565605 | 0.87 | PROKR2 (0.77) | PROKR2PKMMAPK8MAP3K7TAB1 | |
| SCHEMBL565095 | 0.87 | PROKR2 (0.77) | PROKR2PKMMAPK8MAP3K7TAB1 | |
| SCHEMBL564206 | 0.86 | PROKR2 (0.75) | PROKR2MAPK8ADORA2AADORA1MAP3K7 | |
| SCHEMBL565169 | 0.85 | PROKR2 (0.75) | PROKR2PKMMAPK8 | |
| SCHEMBL565414 | 0.85 | PROKR2 (0.74) | PROKR2MAPK8 | |
| SCHEMBL565130 | 0.85 | PROKR2 (0.73) | PROKR2MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780095-B2 | Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190117668-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117668-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS OF CIRCADIAN AND DIURNAL RHYTHMS USING PROKINETICIN 2 AGONISTS AND ANTAGONISTS | PER2, PROKR2, PROKR1 | PROKR2 2/4885PKM 96/4885HTR2A 24/4885 |
| US-10780095-B2 | Compositions and methods for treating disorders of circadian and diurnal rhythms using prokineticin 2 agonists and antagonists | PER2, PROKR2, PROKR1 | PROKR2 2/4885PKM 96/4885HTR2A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.